CYPHERPUNK TECHNOLOGIES INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
CYPHERPUNK TECHNOLOGIES INC. (CYPH) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value of $2.09 per share as of 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2023-11-13
- 2023-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $2.09.
- 2023-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $2.66.
- 2023-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $0.25.
- 2022-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $11.07; Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value as first filed $1.10.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value as first filed |
|---|---|---|
| 2023-09-30 | $2.09 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $2.66 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $0.25 10-Q · filed 2023-05-15 | |
| 2022-09-30 | $11.07 10-Q · filed 2023-11-13 | $1.10 10-Q · filed 2022-11-14 |
| 2022-06-30 | $13.48 10-Q · filed 2023-08-14 | $1.35 10-Q · filed 2022-08-12 |
| 2022-03-31 | $1.39 10-Q · filed 2023-05-15 | |
| 2021-09-30 | $1.37 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $2.21 10-Q · filed 2022-08-12 | |
| 2021-03-31 | $1.57 10-Q · filed 2022-05-13 | |
| 2020-09-30 | $1.33 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $2.18 10-Q · filed 2021-08-13 | |
| 2020-03-31 | $1.48 10-Q · filed 2021-05-14 | |
| 2019-12-31 | $1.76 10-K · filed 2020-03-16 | |
| 2017-03-31 | $9.85 10-Q · filed 2017-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |